Document is current
Any future updates will be listed below
-
Authors
Heiskanen, Marja A.
Honkala, Sanna M.
Hentilä, Jaakko
Ojala, Ronja
Lautamäki, Riikka
Koskensalo, Kalle
Lietzén, Martin S.
Saunavaara, Virva
Saunavaara, Jani
Helmiö, Mika
Löyttyniemi, Eliisa
Nummenmaa, Lauri
Collado, Maria C.
Malm, Tarja
Lahti, Leo
Pietiläinen, Kirsi H.
Kaprio, Jaakko
Rinne, Juha O.
Hannukainen, Jarna C. https://orcid.org/0000-0002-8692-4049
-
Funding
Funding for this research was provided by:
Academy of Finland (317332, 272376, 314383, 266286, 295741)
Suomen Kulttuurirahasto
Suomen Kulttuurirahasto
Diabetes Research Foundation of Finland
Juho Vainion Säätiö
Novo Nordisk (NNF17OC0027232, NNF10OC1013354)
Helsinki University Hospital
Government Research Funds
Suomen Lääketieteen Säätiö
Signe ja Ane Gyllenbergin Säätiö
Sigrid Juséliuksen Säätiö
Helsingin Yliopisto
- License Information
-
More Information
Article History
Received: 28 January 2021
Accepted: 3 February 2021
First Online: 24 February 2021
Ethics approval and consent to participate
: Study protocol, patient information, and informed consent are approved by the Ethical Committee of the Hospital District of South-Western Finland (decision 100/1801/2018 §438). The study is conducted according to Good Clinical Practice and the Declaration of Helsinki. The participants receive the detailed study protocol and it is explained both orally and in written text that the participation to the study is voluntary and they have the right to withdraw from the study at any time without explaining the reason. Written informed consent for the study is obtained from all participants before the beginning of the study.
: The results will be presented as means ± SD in order to maintain anonymousity.
: None. The study has not received funding/assistance from a commercial organization.
